Morbidity in HIV-1-infected individuals before and after the introduction of antiretroviral therapy: A longitudinal study of a population-based cohort in Uganda

HIV Medicine

Volumn 12, Issue 9, 2011, Pages 553-561

  Iwuji, C C ^a   Mayanja, B N ^b   Weiss, H A ^c   Atuhumuza, E ^b   Hughes, P ^b   Maher, D ^b,c   Grosskurth, H ^b,c  

^a ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Antiretroviral therapy; HIV; Morbidity; Opportunistic infections; Seroconverters

Indexed keywords

ANTIRETROVIRUS AGENT;

ADOLESCENT; ADULT; ARTICLE; BACTERIAL PNEUMONIA; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE DURATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; RISK FACTOR; SEROCONVERSION; UGANDA;

ADOLESCENT; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; CONFIDENCE INTERVALS; DISEASE PROGRESSION; FEMALE; HIV SEROPOSITIVITY; HIV-1; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; UGANDA; YOUNG ADULT;

EID: 80053052237     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2011.00923.x     Document Type: Article

References (24)

1. UNAIDS. AIDS epidemic update 2009. Available at (accessed 5 January 2010).
2. World Health Organization. Towards universal access: scaling up priority HIV/AIDS intervention in the health sector. Progress report September 2009. Available at (accessed 5 January 2010).
3. Hung C-C, Chang S-C. Impact of highly active antiretroviral therapy on incidence and management of human immunodeficiency virus-related opportunistic infections. J Antimicrobial Chemother 2004; 54: 849-853.
4. Bussmann H, Wester CW, Ndwapi N et al. Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program. AIDS 2008; 22: 2303-2311.
5. Coetzee D, Hildebrand K, Boulle A et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004; 18: 887-895.
6. Etard JF, Ndiaye I, Thierry-Mieg M et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 2006; 20: 1181-1189.
7. Moh R, Danel C, Messou E et al. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. AIDS 2007; 21: 2483-2491.
8. Losina E, Yazdanpanah Y, Deuffic-Burban S et al. The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Cote d'Ivoire. Antivir Ther 2007; 12: 543-551.
9. Cascade Collaboration Project. Effect of ignoring the time of HIV seroconversion in estimating changes in survival over calendar time in observational studies: results from CASCADE. AIDS 2000; 14: 1899-1906.
10. Seyler C, Messou E, Gabillard D, Inwoley A, Alioum A, Anglaret X. Morbidity before and after HAART initiation in Sub-Saharan African HIV-infected adults: a recurrent event analysis. AIDS Res Hum Retroviruses 2007; 23: 1338-1347.
11. Mulder DW, Nunn AJ, Wagner HU, Kamali A, Kengeya-Kayondo JF. HIV-1 incidence and HIV-1-associated mortality in a rural Ugandan population cohort. AIDS 1994; 8: 87-92.
12. Mbulaiteye SM, Mahe C, Ruberantwari A, Whitworth JA. Generalizability of population-based studies on AIDS: a comparison of newly and continuously surveyed villages in rural southwest Uganda. Int J Epidemiol 2002; 31: 961-967.
13. Ministry of Health, Republic of Uganda. National Antiretroviral Treatment and Care. Guidelines for Adults and Children. 2003.
14. Ives NJ, Gazzard BG, Easterbrook PJ. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART) in a London clinic. J Infect 2001; 42: 134-139.
15. Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS 1999; 13: 1933-1942.
16. Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-860.
17. Mocroft A, Sabin CA, Youle M et al. Changes in AIDS-defining illnesses in a London Clinic, 1987-1998. J Acquir Immune Defic Syndr 1999; 21: 401-407.
18. Ministry of Health, Republic of Uganda. National policy guidelines for cotrimoxazole prophylaxis for people with HIV/AIDS. April 2005.
19. Braitstein P, Brinkhof MW, Dabis F et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367: 817-824.
20. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008; 22: 1897-1908.
21. World Health Organization. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. 2009. Available at (accessed 6 January 2010).
22. Bartlett JA, Shao JF. Successes, challenges, and limitations of current antiretroviral therapy in low-income and middle-income countries. Lancet Infect Dis 2009; 9: 637-649.
23. Kitahata MM, Gange SJ, Abraham AG et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360: 1815-1826.
24. Sterne JA, May M, Costagliola D et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373: 1352-1363.